Table 1. Distribution of baseline characteristics based on conventional 25-OHD levels.
| Serum 25-OHD<20 ng/ml(n = 207) | Serum 25-OHD20–30 ng/ml(n = 141) | Serum 25-OHD>30 ng/ml(n = 114) | Patients notIncluded*(n = 112) | |
| Age at index date (years) Median (IQR) | 70(64–75) | 71(65–76) | 71(66–77) | 70.5(66–75) |
| Charlsonscore Median (IQR) | 2(1–2) | 2(1–3) | 2(1–3) | 2(1–3) |
| Smoking (years) Median (IQR) | 38.5(27–51) | 38.5(27–53.5) | 38(25–49) | 39.5(25–50) |
| Neutrophils (×10∧9/L) Median (IQR) ** | 6.08(4.42–7.28) | 6.35(4.77–8.94) | 6.30(4.93–9.46) | 6.87(4.98–8.78) |
| FEV1 (L) Median (IQR) | 0.93(0.73–1.17) | 0.87(0.69–1.1) | 0.85(0.64–1.12) | 0.88(0.71–1.18) |
| FEV1 predicted (%) Median (IQR) | 40.38(31.72–48.15) | 36.87(30.00–47.94) | 38.45(29.73–48.21) | 37.46(30.37–44.68) |
| FVC (L) Median (IQR) | 2.04(1.59–2.48) | 2.00(1.50–2.40) | 1.85(1.43–2.32) | 2.04(1.62–2.44) |
| BMI ** Median (IQR) | 24.57(20.69–28.58) | 24.31(21.45–27.56) | 23.16(20.15–26.12) | 23.95(21.03–27.57) |
| Present smokers n (%) *** | 97(46.63) | 43(30.50) | 40(35.09) | 44(43.14) |
| Male gender n (% ) | 108(52.17) | 71(50.35) | 51(44.74) | 59(57.84) |
| Randomization Azithromycin n (%) | 102(49.28) | 77(54.61) | 57(50.00) | 48(47.06) |
*
Patients without eligible serum samples.
**
Significant difference between groups using Kruskal-Wallis equality-of-populations rank test.
***
Significant difference between groups using X2 test.